Hospital Pricing Across Europe: Country by Country

Using the iFHP Data — and Understanding Its Limits

The International Federation of Health Plans' 2024 comparative price report is the most widely cited benchmark for international healthcare costs across European markets. The figures are real and useful — for what they describe. What they describe is what domestic commercial payers pay under negotiated contracts in their home markets. That is not the same as what a foreign insurer arriving without a pre-negotiated agreement will be quoted.

The iFHP 2024 data documents a U.S. median cost for coronary artery bypass surgery of $89,094, against $10,734 across Spanish payers in the same study.¹ That $78,000 gap is directionally accurate as a signal that Spain operates at dramatically lower cost than the United States for domestic commercial payers. It is not a reliable price for a specific case. The Spanish figure reflects the public-sector weighted average across Spanish commercial payers with domestic contracts — not what a foreign insurer will be quoted at a private Spanish hospital for the same procedure.

This caveat applies throughout this article wherever iFHP data is cited. The numbers are accurate descriptions of domestic contracted medians. They are the starting reference point for understanding relative cost levels — not the operational benchmark for international patient billing.

Germany: G-DRG, Wahlleistungen, and Length of Stay

Germany implemented the G-DRG (German Diagnosis Related Groups) system for inpatient pricing in 2004. Inpatient care at statutory hospitals is priced by diagnosis and procedure group, with base rates set at the federal level and adjusted by state-level multipliers. This creates more pricing predictability than the U.S. chargemaster system — but it does not eliminate the international premium problem.

Germany's hospital landscape includes both statutory (public and non-profit) hospitals and private hospital groups — Helios, Asklepios, and Rhön-Klinikum are the dominant private networks. These private hospitals operate alongside the statutory sector and bill international patients at rates that may include Wahlleistungen — amenity supplements for private room, named physician, and other services that sit on top of DRG base rates and are specifically targeted at patients not covered by statutory German insurance.

Germany has some of the highest average acute care lengths of stay in Europe. For international payers, this is a significant cost driver that has less to do with pricing structure and everything to do with discharge planning. A patient who remains in a German acute care facility for two weeks post-surgery because rehabilitation placement has not been coordinated is generating entirely avoidable costs. Active length-of-stay management and step-down placement are the primary management priorities in German cases.

France: T2A, Cliniques Privées, and Specialist Honoraires

France implemented T2A (Tarification à l'Activité), its activity-based DRG equivalent, in 2004 for public hospitals. T2A pricing is set nationally and applies uniformly to public facilities — it is genuinely regulated and predictable for cases managed within the public system.

The private sector complicates the picture. Private clinics (cliniques privées) account for approximately 25% of French hospital activity and negotiate their tariffs differently from public hospitals. Specialist fees (honoraires) at private facilities are separately negotiated and are not capped by T2A — a French specialist in a private setting can bill at rates significantly above what T2A covers, and foreign payers are the least protected from this exposure.

For international payers, the operative distinction is whether the patient is in a public hospital (T2A pricing, predictable) or a private clinic (negotiated tariffs, specialist honoraires, and more exposure to international rate premiums). Identifying the care setting at first notification is the critical first step.

United Kingdom: NHS Tariff vs. Private Market Reality

The NHS provides healthcare at effectively no point-of-use cost to UK residents, but international visitors are charged for non-emergency care at national tariff rates — regulated and, for most procedures, significantly below private market rates.

The UK private market operates on entirely different economics. Nuffield Health, Spire Healthcare, and HCA UK are the major private networks. Their pricing is not regulated by NHS tariff. For procedures where private UK rates apply, costs can be higher than equivalent European markets — a fact that surprises payers who assume "UK = NHS = low cost." The NHS cost advantage does not extend to private facilities, which is where most internationally-insured patients end up.

Medical tourism flows into the UK are real, particularly for oncology and specialist procedures at London teaching hospitals' private wings. The assumption that UK private care is a cost-controlled environment is incorrect.

Spain: Seventeen Systems, Six Major Private Groups

Spain's healthcare system is decentralized across 17 Comunidades Autónomas, each of which manages its own health budget, sets its own public-sector tariffs, and negotiates independently with providers. Catalonia's pricing structure differs from Madrid, which differs from Andalucía and the Basque Country. Treating Spain as a single pricing environment is an operational error.

The iFHP 2024 median of $10,734 for coronary bypass across Spanish payers¹ is useful as directional evidence that Spain sits far below the U.S. at the domestic contracted median. It tells an international payer almost nothing about what they will be quoted at a private Spanish hospital without a pre-negotiated agreement.

Spain's private hospital market is dominated by several large groups, each with its own pricing structure, payer contracts, and approach to international patient billing:

• Quirónsalud — the largest private hospital network in Spain, with over 50 hospitals. Owned by Fresenius (Germany). Dominant in Madrid and Barcelona. Maintains the most sophisticated international billing infrastructure of any Spanish private group, with dedicated international patient departments that actively manage foreign-payer revenue. A contract with Quirónsalud provides access to Quirónsalud rates — it does not extend to other groups. The group's signaled expansion as of 2025 is increasing its pricing power relative to payers.^3,4
• HM Hospitales — strong presence in Madrid and Galicia. HM Sanchinarro has a strong oncology reputation. Different pricing structure and contract terms from Quirónsalud.
• Vithas — approximately 20 hospitals with regional distribution across southeastern Spain and the Canary Islands. Pricing and contract terms differ from the Madrid-anchored groups.
• HLA / Grupo Hospitalario HLA (Asisa) — 18 hospitals and 39 clinics, with €676M in revenue in 2024. Insurance-backed ownership structure through Asisa mutualidad, which creates different incentives in contract negotiation than investor-owned groups.⁴
• Ribera Salud — operates under a concession model, managing public hospitals under private management contracts. Pricing dynamics are distinct from pure private facilities and require specific knowledge to navigate.
• Hospiten — significant presence in the Canary Islands and tourist-corridor locations. Patient mix is heavily international, which is reflected in billing approach. Relevant for payers with Canary Islands or resort-destination exposure.
• Sanitas Hospitales — owned by Bupa. Strong Madrid presence. Given Bupa's international orientation, Sanitas has established infrastructure for managing foreign payer cases.

A foreign insurer presenting at any of these groups without a pre-negotiated agreement faces that group's international list tariff, not the contracted rates that domestic Spanish mutuas pay. Each group contracts independently — a relationship with one provides no leverage at another.

Tourist-area private hospitals in the Balearic Islands and the Costa del Sol present dynamics similar to Mexico's tourist corridors: a patient mix that is heavily foreign, billing practices that reflect that mix, and rates for international-insured patients that can diverge significantly from what Spanish nationals pay at the same facility.

Switzerland: European Regulation, Near-U.S. Costs

Switzerland operates under SwissDRG — a regulated diagnosis-related group system — but with base rates that are among the highest in Europe. Complex cases at Swiss private hospitals can approach U.S. pricing levels: a fact that routinely surprises payers who assume "European healthcare" means lower cost than the United States.

Switzerland is not a low-cost European market. For high-acuity cases — cardiac surgery, oncology, complex orthopedics — total procedure costs at Swiss private hospitals are genuinely in a different tier from the rest of continental Europe. Payers without specific Swiss pricing intelligence and established hospital relationships face significant exposure.

Portugal: A Dedicated Section for a High-Priority Market

Netherlands, Belgium, and Scandinavia

The Netherlands uses a system of DBCs (Diagnose Behandeling Combinaties) — product-line pricing that bundles the full episode of care. Belgium operates under its own DRG variant. Both markets are generally predictable for international payers with appropriate operational knowledge, though "predictable" is not "inexpensive."

Scandinavian countries — Sweden, Norway, Denmark — have regulated pricing but with very high labor costs that make total procedure costs higher than southern European equivalents even under regulatory price controls. For complex cases in Scandinavian markets, the primary management challenge is cost arithmetic: each individual element of care may be regulated, but the total procedure cost at high labor rates can rival Western European private markets at their most expensive.

"In regulated public European systems, the primary cost management challenge is clinical coordination — appropriate discharge, rehabilitation placement, step-down care. In European private hospital markets, the challenge is financial: negotiating to contracted domestic rates rather than international list prices, across a fragmented provider landscape where each group contracts independently."